Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET
Company Participants
Ted Jenkins - Vice President-Investor Relations & Strategic Finance
Ankit Mahadevia - Chief Executive Officer
David Melnick - Consultant & Senior Clinical Advisor
Sath Shukla - Chief Financial Officer
Conference Call Participants
Ritu Baral - Cowen
Louise Chen - Cantor
Boobalan Pachaiyappan - H.C. Wainwright
Operator
Good afternoon, and welcome to the Spero Therapeutics Second Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following the company’s formal remarks, we will open up the call for questions. Please be advised that this call is being recorded and a replay will be available. You can find information on the replay and further information related to today's announcement on the Spero Therapeutics website at www.sperotherapeutics.com.
At this time, I would like to turn the call over to Ted Jenkins, Vice President, Investor Relations and Strategic Finance at Spero Therapeutics. Mr. Jenkins, please go ahead.
Ted Jenkins
Thank you, operator and thank you all for participating in today's conference call. This afternoon Spero Therapeutics released financial results and provided a pipeline update for the second quarter of 2022. Our press release is available on the Investor page of the Spero Therapeutics website.
Before we begin, I'd like to remind you that some of the information contained in the news release and on this conference call contains forward-looking statements based on our current expectations; including statements about the potential review, status and prospects of approval for tebipenem HBr and the timing thereof; potential value of tebipenem HBr if approved and the prospects of partnership or other opportunities for the tebipenem HBr program; the plans for the company's ongoing development of SPR720 and SPR206; the design, initiation, timing, progress and the results of the company's preclinical studies and the clinical trials and its research and development programs; management's assessment of the results of such preclinical studies and clinical trials; the company's cash forecast and anticipated expenses and the sufficiency of its cash resources.
Such forward-looking statements are not a guarantee of performance and the company's actual results could differ materially from those contained in such statements. Several factors that could cause or contribute to such differences are described in detail in Spero Therapeutics' filings with the SEC including in the Risk Factors section of our annual report on Form 10-K -- excuse me Form 10-Q filed today.